Suggested remit: To appraise the clinical and cost effectiveness of etranacogene dezaparvovec within its marketing authorisation for treating moderately severe or severe haemophilia B.
Status Awaiting development
Decision None selected
Process STA 2018
ID number 3812

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
29 March 2022 (14:00) Scoping workshop
24 January 2022 - 21 February 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual